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Edited by Angel NebredaAbstract Yeast two-hybrid screening was conducted using a hu-
man ovary cDNA library to search for a novel binding protein
using transforming growth factor-beta stimulated clone-22
(TSC-22). The selected protein was fortilin, which has been char-
acterized as a nuclear anti-apoptotic protein. Overexpression of
fortilin in ovarian carcinoma cells reversed TSC-22-mediated
apoptosis, and the inhibition of fortilin expression via small inter-
fering RNA (siRNA) resulted in an increase in the apoptosis of
ovarian carcinoma cells. Moreover, fortilin overexpression pro-
moted the degradation of TSC-22. Thus, an interaction between
fortilin and TSC-22 prevents apoptosis via the destabilization of
TSC-22 in ovarian carcinoma cells.
Structured summary:
MINT-6173230, MINT-6173253:
TSC22 (uniprotkb:Q15714) physically interacts (MI:0218)
with fortilin (uniprotkb:P13693) by co-immunoprecipitation
(MI:0019)
MINT-6173217:
TSC22 (uniprotkb:Q15714) binds (MI:0407) fortilin (uni-
protkb:P13693) by pull-down (MI:0096)
MINT-6173240, MINT-6173270:
TSC22 (uniprotkb:Q15714) physically interacts (MI:0218)
with fortilin (uniprotkb:P13693) by two-hybrid (MI:0018)
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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TSC-22; Yeast two hybrid1. Introduction
TGF-b stimulated clone 22 (TSC-22) was initially identiﬁed
as one of the genes induced by TGF-b1 treatment [1,2]. TSC-22
is evolutionarily conserved to a signiﬁcant degree from fruitbbreviations: DAPI, 4,60-diamidino-2-phenylindole; GST, glutathi
ne S-transferase; ONPG, o-nitrophenyl b-D-galactopyranoside; sifor
ilin, siRNA, small interfering RNA; THG-1, TSC-22 homologous
ene-1; TSC-22, transforming growth factor-beta stimulated clone-22
Corresponding author. Fax: +82 2 3290 3507.
-mail address: tchun@korea.ac.kr (T. Chun).
Co-ﬁrst authors.
0014-5793/$34.00  2008 Federation of European Biochemical Soc
doi:10.1016/j.febslet.2008.01.066-
-ieties. Puﬂies to mammals [3,4]. The structure of TSC-22 includes a leu-
cine zipper-like motif, thereby suggesting that TSC-22 func-
tions as a transcriptional factor, but lacks the conventional
DNA binding motif at the N-terminal region [1]. Recently, sev-
eral roles of TSC-22 have been proposed, including the regula-
tion of embryogenesis [3,5], and the pro-apoptotic factor in
several cancer cells [6–9].
TSC-22 exists within the cytoplasm in the steady state and
translocates to the nucleus, and there activates signal transduc-
tion to TSC-22 [10]. After nuclear translocation, TSC-22 may
form a homodimer or heterodimer with TSC-22 homologous
gene-1 (THG-1), and operate as a transcriptional repressor
of several genes [11]. This result suggests that TSC-22 may
mediate apoptosis via a caspase-3 dependent pathway [12].
However, the precise mechanism underlying the regulation of
TSC-22 activity has yet to be precisely elucidated.
In order to characterize the TSC-22-dependent apoptotic
pathway, we ﬁrst employed a yeast two-hybrid system to
screen a human ovary cDNA library for novel TSC-22 binding
proteins. We identiﬁed fortilin, a recently characterized nuclear
anti-apoptotic factor. The results of transient transfection
analyses then demonstrated that fortilin overexpression blocks
TSC-22-mediated apoptotic activity via the induction of TSC-
22 degradation. Therefore, these results support the notion
that a dynamic equilibrium existing between pools of TSC-22
and fortilin regulates an apoptotic homeostasis.2. Materials and methods
2.1. Yeast two-hybrid screening
For bait construction with human TSC-22, cDNA encoding for full-
length human TSC-22 was subcloned into the EcoRI and XhoI restric-
tion sites of the pGilda cloning vector. The resultant plasmid, pGilda-
TSC-22, was then introduced into the EGY48 yeast strain [MATa,
his3, trp1, ura3-52, leu2::pLeu2-LexAop6/pSH18-34 (LexAop-lacZ re-
porter)] via a modiﬁed lithium acetate technique [13]. The ovary cDNA
library was then constructed by cloning the cDNA fragments into the
EcoRI and XhoI restriction sites of pJG4-5, thus generating B42 fusion
proteins (Clontech, Palo Alto, CA, USA). The cDNAs encoding for
the B42 fusion proteins were introduced into competent yeast cells that
already harbored pGilda-TSC-22, and the transformants were selected
for tryptophan prototrophy (plasmid marker) on synthetic medium
(Ura, His, Trp) containing 2% (w/v) glucose.
2.2. Quantitation of interaction
The activity of the interaction between TSC-22 and fortilin was ver-
iﬁed via measurements of the relative levels of b-galactosidase expres-blished by Elsevier B.V. All rights reserved.
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previously described protocols [14], with slight modiﬁcation. In brief,
yeast cells (EGY48 strain) containing each construct were cultured in
yeast synthetic media (Ura, His, Trp) with 2% (w/v) glucose until they
achieved mid-growth phase. The cells were then transferred to a yeast
medium (Ura, His, Trp) containing 2% (w/v) galactose and 0.2% di-
methyl sulfoxide (Me2SO). After transformation, equivalent numbers
of cells were lysed in 0.7 ml of Z buﬀer (60 mM Na2HPO4, 40 mM
NaH2PO4, 10 mM KCl, 1 mM MgSO4, and 50 mM b-mercap-
toethanol, pH 7.0) containing 50 ll of 0.1% SDS and 50 ll of chloro-
form for 30 s at 30 C. b-Galactosidase activity was then measured via
the addition of 140 ll of 4 mg/ml r-nitrophenyl b-D-galactopyranoside
(ONPG). The reaction was conducted at 30 C until a yellow color
formed, and was then quenched via the addition of 0.4 ml of 1 M
Na2CO3. The samples were then brieﬂy centrifuged to remove any
remaining cell debris, and the absorbance was measured at wave-
lengths of 420 and 550 nm. b-Galactosidase activity was calculated
using the formula units = [1000 · (A420  1.75 · A550)]/(time · vol-
ume · A600).2.3. In vitro pull-down assay
cDNA encoding for human TSC-22 was subcloned into the EcoRI
and XhoI restriction sites of the pGEX4T-1 vector (GE Healthcare,
Piscataway, NJ, USA) to generate the glutathione S-transferase
(GST) fusion protein (GST-TSC-22). Human fortilin cDNA was li-
gated into pET28a (Novagen, Madison, WI, USA) using EcoRI and
XhoI, thereby generating a histidine fusion protein (His-fortilin).
The GST and histidine fusion proteins were puriﬁed using either a
GST column (GE Healthcare) or an Ni2+ column (Novagen), in accor-
dance with the manufacturers protocols. The puriﬁed GST-TSC-22
(2 lg) was then mixed with His-fortilin (2 lg). The mixtures were sub-
sequently added to 20 ll of a GST column matrix (glutathione sephar-
ose 4B, GE Healthcare) and incubated for 30 min at 25 C. The slurry
was pelleted via centrifugation and washed. The pellet of the gel matrix
was resuspended in 20 ml of elution buﬀer (10 mM glutathione, 50 mM
Tris–HCl, pH 8.0) and incubated for 20 min at 25 C in order to elute
the bound GST fusion proteins. The eluted proteins were separated via
gel electrophoresis, and the proteins were detected by Coomassie stain-
ing.
2.4. Co-immunoprecipitation
For co-immunoprecipitation, SKOV-3 ovarian cancer cells were
washed in PBS and resuspended in cell lysis solution (50 mM Tris–
HCl, pH 7.2, 150 mM NaCl, 1% Triton X-100, 1 lg/ml leupeptin ml,
1 lg/ml pepstatin ml, 2 lg/ml aprotinin, 200 lg/ml PMSF). The lysates
were then incubated with goat anti-fortilin antibody (sc-20426, Santa
Cruz Biotechnology), goat anti-TSC-22 antibody (sc-27844, Santa
Cruz Biotechnology) or goat IgG (sc-2028, Santa Cruz Biotechnology),
and precipitated with protein A-agarose (GE Healthcare). The precip-
itated proteins were resolved via SDS gel electrophoresis, transferred
onto Immobilon P membranes (Millipore Corporation, Billerica,
MA, USA), and immunoblotted with anti-TSC-22 antibody or anti-
fortilin antibody using the ECL system (GE Healthcare). b-Actin anti-
body (sc-69879, Santa Cruz Biotechnology) was employed as an inter-
nal control.
2.5. Subcloning of deletion mutants of fortilin and TSC-22
Three deletion mutants (Met1-Asp52, Asn53-Phe110, Gln111-Ala144) of
TSC-22 were isolated by PCR using the combination of the following
primers (TSC-22-F1, 5 0-CGGGAATTCATGAAATCCCAATGGT-
GT-3 0; TSC-22-R1, 5 0-ATTCTCGAGTCAGTCAATAGCTACCAC-
3 0; TSC-22-F2, 5 0-CGGGAATTCAACAAAATCGAGCAAGCT-3 0;
TSC-22-R2, 50-ATTCTCGAGTCAAAACTGGGCAAGCTG-30; TSC-
22-F3, 5 0-CGGGAATTCCAGGCCCAGCTGCAGACT- 3 0; TSC-
22-R3, 5 0-CGGCTCGAGCTATGCGGTTGGTCCTGA-3 0). PCR
products spanning each fragment were cloned into the EcoRI and
XhoI restriction sites of the pGilda. Three deletion mutants (Met1-
Gly69, Val70-Ala119, Glu120-Cys172) of fortilin were isolated by poly-
merase chain reaction (PCR) using the combination of the following
primers (fortilin-F1, 5 0-CGGGAATTCATGATTATCTACCGG-
GAC-30; fortilin-R1, 5 0-CGGCTCGAGTCAACCAGTGATTACT-
GT-3 0; fortilin-F2, 5 0-CGGGAATTCGTCGATATTGTCATGAAC-
3 0; fortilin-R2, 5 0-ATTCTCGAGTCATGC AGCCCCTGTCAT-3 0;
fortilin-F3, 5 0-CGGGAATTCGAACAAATCAAGCACATC-3 0; for-tilin-R3, 5 0-CGGCTCGAGTTAACATTTTTCCATTTC-30). PCR
products spanning each fragment were cloned into the EcoRI and
XhoI restriction sites of the pJG4-5. Each constructed plasmid was
introduced into yeast EGY48 expressing either fortilin or TSC-22 hy-
brid protein.
2.6. Small interfering RNA (siRNA) construction
The siRNA oligonucleotide sequence targeting TSC-22 (5 0-
GGCGATGGATCTAGGAGTT-3 0) corresponded to nucleotides
27–45 in the human sequence, and the siRNA oligonucleotide sequence
targeting fortilin (5 0-AAGGTACCGAAAGCACAGT-30) corre-
sponded to nucleotides 179–197 in the human sequence. siRNA was
synthesized using an siRNA construction kit (Ambion, Austin, TX,
USA) and was then transfected by oligofectamine (Invitrogen), in
accordance with the manufacturers protocols. After transfection of
siRNA, the mRNA and protein expression levels of both fortilin and
TSC-22 were compared to transfectants with either cDNA constructs
of pEGFPC1-fortilin or pEGFPC1-TSC-22 by RT-PCR and immuno-
blot as described above.
2.7. Cell viability assay
SKOV-3 ovarian cancer cells were plated in six-well plates and trans-
fected with the indicated cDNA and/or siRNA. Three days after trans-
fection, the cells were harvested, stained with trypan blue, and counted
under a light microscope. Cell viability assay was also assessed with the
presence of caspase-3 speciﬁc inhibitor, z-DEVD-fmk (50 lM; BDP-
harmingen, San Diego, CA, USA).
2.8. Apoptosis assay
SKOV-3 ovarian cancer cells were plated onto six-chamber slides
and transfected with the indicated cDNA and/or siRNA. For the eval-
uation of nuclear morphology, the nuclei were ﬁxed in methanol and
stained with 4,6 0-diamidino-2-phenylindole (DAPI, 1 lg/mL, Boehrin-
ger Mannheim, Mannheim, Germany) for 15 min and rinsed twice
with PBS, then examined under a ﬂuorescence microscope.
2.9. In vitro caspase-3 activity assay
Caspase-3 enzymatic activity in the cell lysates was evaluated using
acetyl-DEVD-7-amino-4-triﬂuoromethyl coumarin, in accordance
with the manufacturers protocols (BDPharmingen). Activity was as-
sessed using a Spectramax 340 microplate reader (Molecular Devices,
Sunnyvale, USA) in ﬂuorescence mode with an excitation wavelength
of 400 nm and an emission wavelength of 505 nm. Enzyme activity was
calculated and indicated as ﬂuorescence in accordance with the for-
mula provided by the manufacturer (BDPharmingen). Caspase-3 enzy-
matic activity in the cell lysates was also visualized by immunoblot
using anti-caspase-3 antibody (610324, BDPharmingen).
2.10. Determination of TSC-22 protein stability
SKOV-3 ovarian cancer cells were transfected with mock (an expres-
sion vector only without insert), fortilin siRNAs, or co-transfected
with TSC-22 and the indicated pEGFPC1-fortilin cDNA mutant.
Three days after transfection, the cells were treated with cycloheximide
(Sigma) at a ﬁnal concentration of 100 lg/ml. The cell lysates were sub-
sequently harvested at sequential time points after treatment, resolved
via SDS gel electrophoresis, transferred onto Immobilon P membranes
(Millipore Corporation, Billerica, MA, USA), and immunoblotted
with anti-TSC-22 antibody or anti-GFP antibody (sc-8334, Santa Cruz
Biotechnology) using the ECL system (GE Healthcare). b-Actin anti-
body was utilized as an internal control.3. Results and discussion
3.1. Identiﬁcation of fortilin as a TSC-22 binding protein
The human ovary cDNA library fused to the gene for the
transcription activator, pJG4-5, was introduced into yeast cells
harboring pGilda-TSC-22 as bait. Approximately, 3 · 106
independent transformants were pooled and spread again onto
the selection media (Ura, His, Trp, Leu) containing 2%
(w/v) galactose in order to induce cDNA expression. If a
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1212 J.H. Lee et al. / FEBS Letters 582 (2008) 1210–1218B42-tagged protein interacts with the TSC-22, the transcrip-
tion of the LEU2 gene is activated, thus allowing the host cells
to grow on a leucine-deﬁcient synthetic medium. Among the
seven colonies obtained on the selection media, a total of ﬁve
colonies evidenced galactose dependency. The plasmids were
isolated from the selected yeast cells and introduced into Esch-
erichia coli KC8 in order to isolate the plasmids harboring the
pJG4-5-cDNA inserts. The plasmids were then isolated by the
plasmid marker, trp, in the E. coli host, and the puriﬁed plas-
mids were sequenced. A GenBank homology search using the
BLAST program showed that all ﬁve of the plasmids encoded
for human fortilin (GenBank accession number: NM_003295).
In order to verify this result, we determined the binding activ-
ity between TSC-22 and fortilin via measurements of the rela-
tive b-galactosidase expression level. As is shown in Fig. 1A,
the b-galactosidase activity between TSC-22 and fortilin was
clearly observed, whereas very little b-galactosidase activity
was observed between TSC-22 and the empty vector (vector
only).T
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ig. 1. Interaction analysis between human fortilin and TSC-22. (A) Bindin
alactopyranoside (ONPG) assays. b-Galactosidase activity was measured via
nteractions between TSC-22 (GST-TSC-22) and fortilin (His-fortilin) were con
uriﬁed GST-TSC-22 (2 lg) was mixed with His-E-fortilin (2 lg). The protein
roteins were separated via gel electrophoresis, and the proteins were detected
ortilin; 4, GST-TSC-22 and His-fortilin, respectively. The results are represen
ortilin with TSC-22 in human ovarian carcinoma cells, SKOV-3. IP means i
ntibodies. The results are representative of three separate experiments.The interaction between TSC-22 and fortilin was further
evaluated via in vitro pull-down assays and co-immunoprecip-
itation. For the in vitro pull-down analysis, the GST–TSC-22
fusion protein was mixed with His–fortilin, and the mixture
was puriﬁed using a GST column matrix. The eluted proteins
were separated via gel electrophoresis and the proteins were
detected by Coomassie staining. As is shown in Fig. 1B, the
His–fortilin fusion protein, which measured approximately
25 kDa, was co-puriﬁed with the GST–TSC-22 fusion protein
(lane 4). No protein bands were detected when no input was
added to the GST column matrix (lane 1). A single band of
approximately 45 kDa, equivalent to the GST–TSC-22 fusion
protein, was observed when the GST–TSC-22 fusion protein
was added to the GST column matrix (lane 2). However, no
bands were observed when the His–fortilin fusion protein
was added to the GST column matrix (lane 3).
For co-immunoprecipitation, SKOV-3 ovarian cancer cells
were washed in PBS and resuspended in cell lysis solution.
Immunoprecipitation was subsequently conducted usingSC-22 + Fortilin :   93.24 ± 2.26
SC-22 + Vector only :   2.73 ± 0.05
3 4 
TSC-22
Fortilin
IP
WB : Anti-Fortilin
WB : Anti-β-actin
Whole 
cell
lysate goat IgG Anti-TSC-22
g activity of TSC-22 and fortilin measured by r-nitrophenyl b-D-
the addition of ONPG. Data are expressed as the means ± S.E.M. (B)
ﬁrmed via in vitro pull-down assays. For GST pull-down analysis, the
mixtures were then subjected to GST aﬃnity puriﬁcation. The eluted
by Coomassie staining. Lanes: 1, no input; 2, GST-TSC-22; 3, His-
tative of three separate experiments. (C) Co-immunoprecipitation of
mmunoprecipitation and WB means immunoblotting with indicated
J.H. Lee et al. / FEBS Letters 582 (2008) 1210–1218 1213anti-fortilin antibody or anti-TSC-22 antibody with whole
cell lysates. After immunoprecipitation, the precipitated pro-
teins were immunoblotted with anti-TSC-22 antibody or
anti-fortilin antibody. As is shown in Fig. 1D, TSC-22 was
co-immunoprecipitated with fortilin (upper left panel),
whereas no interactions were observed between isotype con-
trol (goat IgG) and TSC-22 (upper left panel). Also, fortilin
was co-immunoprecipitated with TSC-22 (upper right panel),
whereas no interactions were observed between isotype con-
trol (goat IgG) and fortilin (upper right panel). Immunoblot-
ting using anti-TSC-22 antibody and anti-fortilin antibody
veriﬁed that an equal quantity of both fortilin and TSC-22
was present in the whole cell lysates. The whole cell lysates
from both samples harbored the equivalent proteins when
immunoblotted using anti-b-actin antibody (lower panel).
These results clearly demonstrated that TSC-22 and fortilin
interact with each other on the physiological level in
SKOV-3 ovarian cancer cells.A
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To identify the fortilin binding region of TSC-22, cDNA
constructs containing three TSC-22 deletion mutants were de-
signed as shown in Fig. 2A. These truncated regions were pre-
dicted to be predominantly a-helices. In the two-hybrid
system, the full-length human fortilin cDNA and either plas-
mid containing a full-length human TSC-22 cDNA (left panel
in Fig. 2A, full) or plasmids containing three truncation mu-
tant forms (left panel in Fig. 2A, Met1-Asp52, Asn53-Phe110,
Gln111-Ala144) of cDNAs were co-transformed into EGY48
yeast cells. Cells containing full-length TSC-22 cDNA and also
one deletion mutant (Asn53-Phe110) grew on the Ura, His, Trp
and Leu deﬁcient plates. Yeast cells transformed with the other
deletion mutants (Met1-Asp52 and Gln111-Ala144) failed to
grow (right panel in Fig. 2A). To conﬁrm this result, we deter-
mined the binding activity of these constructs by measuring the
relative expression level of b-galactosidase. As shown in rightC-22
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either of these mutants (Met1-Asp52 and Gln111-Ala144) cannot
bind to fortilin. However, we cannot exclude that the fortilin
binding site of TSC-22 is located near the junction of these mu-
tants since b-galactosidase activity in one deletion mutant
(Asn53-Phe110) is lower than full-length TSC-22 (right panel
in Fig. 2A).
Subsequently, cDNA constructs containing three fortilin
truncation mutants were designed to localize the TSC-22 bind-
ing region of fortilin (left panel in Fig. 2B, full). These trun-
cated regions were predicted to be predominantly a-helices.
In the two-hybrid system, full-length human TSC-22 cDNA
and either full-length human fortilin cDNA (left panel in
Fig. 2B, full) or three truncation mutants (left panel in
Fig. 2B, Met1-Gly69, Val70-Ala119, Glu120-Cys172) were co-
transformed into EGY48 yeast cells. Cells containing full-
length fortilin cDNA and also the one deletion mutant
(Met1-Gly69) grew on the Ura, His, Trp and Leu deﬁcient
plates. Yeast cells transformed with the other deletion mutants
(Val70-Ala119, Glu120-Cys172) failed to grow (right panel in
Fig. 2B). We also quantitated the binding activity of these con-
structs by measuring relative expression level of b-galactosi-
dase. Results on b-galactosidase assay also indicated that the
critical fortilin region for binding TSC-22 resided within
Met1-Gly69 (right panel in Fig. 2B).
To conﬁrm these results, one deletion mutant of fortilin
(Met1-Gly69) and either vector cDNA or three truncation mu-
tants of TSC-22 (Met1-Asp52, Asn53-Phe110, Gln111-Ala144)
were co-transformed into EGY48 yeast cells (Fig. 2C). Consis-
tent with results from Fig. 2A and B, cells containing fortilin
deletion mutant (Met1-Gly69) with one TSC-22 deletion mu-GFP-TSC-22
GFP-TSC-22
+ siRNA
Tsc-22 mRNA
Gapdh mRNA
Anti-TSC-22
Anti-β-actin
GFP-TSC-22
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ig. 3. The construction of siRNA system that inhibits TSC-22 and fortilin.
DNA alone or co-transfected each GFP fused cDNA with each siRNA. After
nd analyzed the mRNA or protein expression levels by RT-PCRs and immuno
xperiments.tant (Asn53-Phe110) only grew on the Ura, His, Trp and Leu
deﬁcient plates whereas the other deletion mutants (Val70-
Ala119, Glu120-Cys172) failed to grow. Subsequent results on
b-galactosidase assay were also agreed with these results
(Fig. 2C).
3.3. Overexpression of TSC-22 can induce apoptosis in SKOV-3
ovarian cancer cells via caspase-3 dependent pathway
To evaluate the functional consequences of the interaction
taking place between TSC-22 and fortilin, we conducted a cou-
ple of experiments involving mammalian cell apoptosis. First,
we attempted to construct siRNA system that inhibits TSC-22
and fortilin since both proteins endogenously express in
SKOV-3 ovarian cancer cells. To test whether siRNA transfec-
tion eﬃciently blocks endogenous TSC-22 or fortilin, we mea-
sured both mRNA and protein expression levels of siRNA and
overexpression co-transfectants as well as overexpression
transfectants. As shown in Fig. 3, the mRNA and protein
expression levels of both TSC-22 and fortilin in siRNA and
overexpression co-transfectants (lane 2 in Fig. 3) were signiﬁ-
cantly decreased comparing with overexpression transfectants
(lane 1 in Fig. 3).
Next, we determine whether TSC-22 overexpression induces
apoptosis in SKOV-3 cells. As is shown in Fig. 4A, the viabil-
ity of the SKOV-3 cells is gradually reduced in a transfected
TSC-22 cDNA dose-dependent manner, and nearly 50% of
cells died when 1 lg of TSC-22 cDNAs was transfected. This
result is also supported by immunoblot analysis using cas-
pase-3 antibody. Only activated form of caspase-3 was ob-
served in TSC-22 transfectant, not in both mock and siTSC-
22 (siRNA of TSC-22) transfectants (Fig. 4B). To conﬁrmGFP-Fortilin
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blots. Size bar, 20 lm. The results are representative of three separate
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Fig. 4. TSC-22 mediated apoptosis via caspase-3 dependent pathway
in human ovarian carcinoma cells, SKOV-3. (A) SKOV-3 ovarian
cancer cells were transfected with mock (an expression vector only
without insert) or TSC-22 cDNA. Three days after transfection, the
cells were stained with trypan blue and quantitated to analyze cell
viability. Data are expressed as the means ± S.E.M. (B) SKOV-3
ovarian cancer cells were transfected with mock (an expression vector
only without insert), siRNA of TSC-22 (siTSC-22) or TSC-22 cDNA.
The cells were harvested and caspase-3 was detected by immunoblot
using anti-caspase-3 antibody. The results are representative of three
separate experiments. (C) A caspase-3 speciﬁc inhibitor, z-DEVD-fmk,
was treated in mock or TSC-22 transfectants. The cells were stained
with trypan blue and quantitated to analyze cell viability. Data are
expressed as the means ± S.E.M.
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caspase-3, in TSC-22 transfectant. As a result, z-DEVD-fmk
treatment deﬁnitively restores viability of TSC-22 transfectant
(Fig. 4C). Thus, 1 lg of TSC-22 cDNAs was utilized as the
treatment concentration in all of the following experiments.
3.4. Fortilin prevents TSC-22 mediated apoptosis via the
destabilization of TSC-22
Fortilin is a highly conserved hydrophilic nuclear protein,
and is expressed ubiquitously in a variety of cells [15]. The re-
sults of a recent study showed that fortilin overexpression can
prevent stress-induced mammalian cell apoptosis [15,16]. Con-
versely, the inhibition of fortilin in malignant human carci-
noma cells induced an increase in apoptosis [15,16]. Thus,
fortilin may be relevant to cell survival as a negative apoptotic
regulator. However, the exact mechanism underlying the anti-
apoptotic eﬀects of fortilin remains to be clearly elucidated.
Therefore, we attempted to determine whether TSC-22 and
fortilin evidence an additive eﬀect or antagonize each other
upon apoptosis.
As shown in Fig. 5A, nearly 50% of the cells perished after
transfection with TSC-22 cDNA alone as compared to the
mock transfectant, whereas no change in cell viability was ob-
served when the cells were transfected with fortilin cDNA
alone (Fig. 5A). Consistent with previous observation
[15,16], the fortilin siRNA transfectant shows decreased cell
viability, similar level as that of TSC-22 transfectant
(Fig. 5A). Interestingly, cell viability largely recovered upon
co-transfection with TSC-22 and fortilin cDNAs (Fig. 5A).
This suggests that fortilin may antagonize the TSC-22-medi-
ated apoptosis of SKOV-3 cells. In order to verify this result,
we inhibited fortilin expression by siRNA when we transfected
the cells with TSC-22 cDNA. As is shown in Fig. 5A, the via-
bility of TSC-22 and the sifortilin (siRNA of fortilin) co-trans-
fectant was greatly reduced as compared to the TSC-22 and
fortilin co-transfectant.
To verify that the reduction in cell numbers was reﬂective of
apoptosis, we employed DAPI staining to conﬁrm the ob-
served reduced proliferation in SKOV-3 cells overexpressing
mock (expression vector only), fortilin, sifortilin, TSC-22, or
siTSC-22, or co-transfected with TSC-22 and fortilin cDNAs,
co-transfected with TSC-22 and sifortilin, or co-transfected
with TSC-22 and sifortilin, or triple-transfected with fortilin,
sifortilin and TSC-22. As had been expected, after transfection
with TSC-22 cDNA alone compared to mock transfectant,
nearly 60% of the cells evidenced fragmented nuclei, whereas
no change in cell viability was observed when the cells were
transfected with mock and fortilin cDNA alone. Cells transfec-
ted with a combination of TSC-22 and fortilin evidenced a sig-
niﬁcantly reduced number of cells harboring fragmented
DNA, but cells transfected with fortilin-siRNA did not
(Fig. 5B). We subsequently assessed the caspase-3 activity in
those transfectants. As is shown in Fig. 5C, no signiﬁcant
changes in caspase-3 activity were observed in the cells trans-
fected with fortilin cDNA alone, as compared to the mock-
transfected cells. A signiﬁcant upregulation of caspase-3 activ-
ity was detected in the cells transfected with TSC-22 cDNA
alone compared to the mock-transfected cells (Fig. 5C). How-
ever, caspase-3 activity was reduced by almost half in the co-
transfectant harboring both TSC-22 and fortilin cDNAs as
compared to the transfectant harboring TSC-22 cDNA alone
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Fig. 5. Fortilin inhibits TSC-22 mediated apoptosis in human ovarian carcinoma cells, SKOV-3. Cell viability assay (A), DAPI staining (B) and
caspase-3 activity assay (C) were performed on SKOV-3 ovarian cancer cells transfected with mock (an expression vector only without insert),
fortilin, sifortilin, TSC-22 or siTSC-22, or co-transfected with TSC-22 and fortilin cDNAs, co-transfected with TSC-22 and sifortilin, or co-
transfected with TSC-22 and sifortilin, or triple-transfected with fortilin, sifortilin and TSC-22. (A) Cell viability assay was quantiﬁed via tryptophan
blue staining. Data are expressed as the means ± S.E.M. (B) Cells were stained with DAPI to visualize DNA fragmentation for the apoptosis assay.
Arrows indicate the observed DNA fragmentations. Size bar, 20 lm. The results are representative of three separate experiments. (C) Caspase-3
activity was measured using a microplate reader in ﬂuorescence mode with an excitation wavelength of 400 nm and an emission wavelength of
505 nm. Enzyme activity was calculated and indicated as ﬂuorescence in accordance with the formula provided by the manufacturer. Data are
expressed as the means ± S.E.M.
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containing both TSC-22 cDNA and sifortilin was restoredmarkedly, to almost the same levels observed in the cells trans-
fected with TSC-22 cDNA alone. These results clearly showed
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Fig. 6. Stability of TSC-22 is reduced by fortilin. (A) SKOV-3 ovarian
cancer cells were transfected with mock (an expression vector only
without insert) or fortilin siRNAs. After transfection, the cells were
treated with cycloheximide (100 lg/ml). At each time point, the whole
cell lysates were prepared and analyzed via immunoblot analysis using
antibodies against TSC-22, fortilin or b-actin to measure the amounts
of TSC-22 protein remaining at the respective times. The h refers to
hours after cycloheximide treatment. The results are representative of
three experiments. (B) SKOV-3 ovarian cancer cells were co-transfec-
ted TSC-22 cDNA with the each pEGFPC1-fortilin cDNA mutant
(Met1-Gly69, Val70-Ala119, Glu120-Cys172). The cells were treated with
cycloheximide (100 lg/ml). At 5 h after cycloheximide treatment, the
whole cell lysates were prepared and analyzed via immunoblot analysis
using antibodies against TSC-22, GFP or b-actin to measure the
amounts of TSC-22 and fortilin. The results are representative of three
experiments. (C) SKOV-3 ovarian cancer cells were transfected with
mock (an expression vector only without insert) or TSC-22 cDNA, or
co-transfected TSC-22 cDNA with the each pEGFPC1-fortilin cDNA
mutant (Met1-Gly69, Val70-Ala119, Glu120-Cys172). Three days after
transfection, the cells were stained with trypan blue and quantitated to
analyze cell viability. Data are expressed as the means ± S.E.M.
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human ovarian carcinoma cells.
To deﬁne the mechanism by which fortilin inhibits TSC-22
mediated apoptosis, we assessed the stability of the TSC-22
protein in the presence or absence of fortilin in SKOV-3 cells.
In brief, mock transfectant and sifortilin transfectant were
treated with cycloheximide. Then, the cell lysates were har-
vested at 1 h, 3 h and 5 h after treatment, and immunoblottedwith anti-TSC-22 antibody or anti-fortilin antibody. As is
shown in Fig. 6, the level of TSC-22 protein evidenced a signif-
icant reduction in a time-dependent manner in the presence of
fortilin. Conversely, the level of TSC-22 protein evidenced no
signiﬁcant change for over 5 h in the absence of fortilin
(Fig. 6A). To conﬁrm this result, we co-transfected TSC-22
cDNA with the each pEGFPC1-fortilin cDNA mutant
(Met1-Gly69, Val70-Ala119, Glu120-Cys172) and performed
TSC-22 stabilization assay and cell viability test using these
co-transfectants. For TSC-22 stabilization assay, we harvested
cell lysates at 5 h after cycloheximide treatment, and immuno-
blotted with anti-TSC-22 antibody or anti-GFP antibody. As
shown in Fig. 6B, the level of TSC-22 protein was signiﬁcant
decreased in co-transfectant containing TSC-22 cDNA and
one deletion fortilin mutant (Met1-Gly69). Also, cell viability
in co-transfectant containing TSC-22 cDNA and one deletion
fortilin mutant (Met1-Gly69) was recovered, compared to
transfectant containing TSC-22 cDNA alone (Fig. 6C). How-
ever, neither the level of TSC-22 protein nor cell viability
was changed in co-transfectants containing TSC-22 cDNA
and the other deletion mutant (Val70-Ala119, Glu120-Cys172).
These results clearly showed that the interaction between for-
tilin and TSC-22 accelerates the destabilization of TSC-22 in
SKOV-3 human ovarian carcinoma cells.
In this study, we have described the speciﬁc interaction
occurring between TSC-22 and fortilin, a highly conserved
anti-apoptotic protein [15,16]. The interaction between TSC-
22 and fortilin appears to be physiologically relevant, as this
interaction occurs in both yeast and mammalian cells. Our re-
sults also show that fortilin binds to and destabilizes TSC-22.
TSC-22 and fortilin are both localized predominantly within
the nucleus. During apoptosis, activated TSC-22 moves from
the cytosol to the nucleus and functions as a transcriptional
repressor of several genes [10]. Fortilin is a known nuclear-
residing protein, and myeloid cell leukemia 1 protein is known
to stabilize fortilin via direct interaction [17]. Thus, it is likely
that fortilin destabilizes the activity of TSC-22 within the nu-
cleus. Conversely, the weakening activity of fortilin induced
by treatment with sifortilin reversed the apoptotic activity of
TSC-22. Therefore, the interaction between TSC-22 and forti-
lin appears crucial for the regulation of TSC-22-mediated
apoptosis. The results of this study provide valuable informa-
tion as to the mechanisms by which fortilin exerts its anti-
apoptotic protein properties. Further studies in this regard will
focus on the speciﬁc mechanism by which fortilin destabilizes
TSC-22 in the nucleus, and will also concern the possible inﬂu-
ence of fortilin on other pro-apoptotic proteins.
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